arrhea and only 5 of the cases (3.3%) were miscoded. Therefore, we believe the rate of misclassification is low and our results are valid.

Sandra Dial MD MSc

Samy Suissa PhD

Department of Medicine, Sir Mortimer B. Davis–Jewish General Hospital, Montréal, Que.

Competing interests: Sandra Dial has received speaker's fees and travel assistance from Glaxo-SmithKline. Samy Suissa is a consultant for Bristol-Myers Squibb. He has received speaker's fees from AstraZeneca and travel assistance from Pfizer.

REFERENCES

1. Dial S, Kezouh A, Dascal A, et al. Patterns of antibiotic use and risk of hospital admission because of *Clostridium difficile* infection. *CMAJ* 2008;179:767-72.
2. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *N Engl J Med* 2005;353:2442-9.
3. Wilcox MH, Mooney L, Bendall R, et al. A case-control study of community-associated *Clostridium difficile* infection. *J Antimicrob Chemother* 2008;62:388-96.
4. Centers for Disease Control. Surveillance for community-associated *Clostridium difficile*. Connecticut, 2006. *Morb Mortal Wkly Rep* 2008;57:340-3.
5. Barbut F, Decré D, Lalande V, et al. Clinical features of *Clostridium difficile*-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyl-transferase)-producing strains. *J Med Microbiol* 2005;54(Pt 2):181-5.
6. Dial S, Delaney C, Baldry C, et al. The risk of *C. difficile* associated disease in patients exposed to prophylactic antibiotics only during a CDAD outbreak. Toronto (ON): American Society of Microbiology; July 7 2007. Available: www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={CD137E74-CF25-4F2F-812A-70A6FA52A861}&SKey={58BE512D-DF46-4A28-8417-1E7CA9F9B777}&MKey={87AF89B1-8D78-42C4-A493-57845C861CB4}&AKey={32093528-52DC-4EBE-9D80-29DAD84C92CE} (accessed 2008 Dec 3).

DOI:10.1503/cmaj.1080125

Corrections

An article¹ in the November 18 issue contained 2 errors. First, in Table 3, the average annual percentage change in mortality for liver cancer should have been listed as a 2.2% increase.

Second, text was omitted from the first and second paragraphs under "Prevalence, incidence, mortality and survival." This section should have read "Despite the higher number of cases and deaths among men, there is a higher incidence of cancer among women aged 20–59 years. The mortal-

ity rates among women in their 30s and 40s are higher than among men of a comparable age.

The prevalence of cancer is also increasing because of the increasing number of new cases each year as well as improved survival. Thus, it is imperative that we better understand the issues faced by cancer survivors. In 2004, there were 850 000 living Canadians who had received a diagnosis of cancer at some time in the previous 15-year period (2.5% of men, 2.8% of women)."

These errors have been corrected in the online version.

REFERENCE

1. Marrett LD, De P, Airia P, et al. Cancer in Canada in 2008. *CMAJ* 2008;179:1163-70.

DOI:10.1503/cmaj.081975

In a research article¹ in the December 2 issue, the second-last sentence in the results section of the abstract should have read "They were also more effective for

patients with severe pneumonia (OR 1.84, 95% CI 1.02–3.29), those who required admission to hospital (OR 1.30, 95% CI 1.04–1.61) and those who required intravenous therapy (OR 1.44, 95% CI 1.13–1.85).

REFERENCE

1. Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. *CMAJ* 2008;179:1269-77.

DOI:10.1503/cmaj.081980

In a research article¹ in the December 2 issue, Brian Hutton should have been acknowledged for his assistance in propensity score matching.

REFERENCE

1. Wen SW, Zhou J, Yang Q, et al. Maternal exposure to folic acid antagonists and placenta-mediated adverse pregnancy outcomes. *CMAJ* 2008;179:1263-8.

DOI:10.1503/cmaj.081981

Letters submission process

To send a letter to the editor concerning a published article, visit www.cmaj.ca and click "Submit a response" at the top right-hand side of the article. All letters submitted through www.cmaj.ca will be considered for publication in the print journal. To submit a letter that does not pertain to an article in the journal, email your letter to pubs@cma.ca with a note indicating whether or not you would like it to be considered for publication.

Letters written in response to an article published in *CMAJ* are more likely to be accepted for print publication if they are submitted within 2 months of the article's publication date. Letters accepted for print publication are edited for length (usually 250 words) and house style.

Mécanisme de présentation des lettres

Pour écrire à la rédaction au sujet d'un article publié dans le *JAMC*, rendez-vous sur le site www.jamc.ca, ouvrez l'article en question et cliquez sur "Submit a response" parmi les choix énumérés en bleu à droite de l'article. On étudiera toutes les lettres reçues sur le site web pour éventuelle publication dans la version imprimée du Journal. Si votre lettre traite d'un autre sujet qu'un article publié dans le Journal, écrivez à pubs@cma.ca et précisez si vous souhaitez ou non que votre lettre soit étudiée en vue de sa publication.

Les lettres répondant à un article publié dans le *JAMC* sont plus susceptibles d'être acceptées pour publication imprimée si elles sont présentées dans les deux mois de la date de publication de l'article. Les lettres acceptées pour publication imprimée sont révisées en fonction du style du *JAMC* et raccourcies au besoin (elles doivent habituellement compter au maximum 250 mots).